Intravenous Immunoglobulin (IVIg)

Intravenous Immunoglobulin (IVIg)

Global Intravenous Immunoglobulin (IVIg) Market to Reach US$34.0 Billion by 2030

The global market for Intravenous Immunoglobulin (IVIg) estimated at US$19.1 Billion in the year 2023, is expected to reach US$34.0 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. IgA, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$13.7 Billion by the end of the analysis period. Growth in the IgE segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 8.0% CAGR

The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Intravenous Immunoglobulin (IVIg) Market - Key Trends and Drivers Summarized

Intravenous Immunoglobulin (IVIG) is a critical component in medical treatments, providing necessary antibodies to those with inadequate immune defenses. Derived from the plasma of thousands of donors, IVIG encompasses a wide array of antibodies essential for combating various pathogens, making it indispensable for individuals with immunodeficiency disorders. By supplementing the body`s antibody requirement, IVIG offers robust protection against a multitude of infections, crucial for patients whose bodies cannot produce sufficient antibodies. Additionally, IVIG plays a significant role in treating autoimmune diseases, where the body`s immune system erroneously attacks its own cells. By introducing a high concentration of antibodies, IVIG helps mitigate this misguided immune response, offering relief for conditions such as immune thrombocytopenia and autoimmune hemolytic anemia, among others.

The administration of IVIG is generally carried out intravenously in a clinical setting, where the dosage and frequency are meticulously tailored to the patient`s specific medical needs and body weight. This personalized approach ensures that patients receive optimal treatment effectiveness with minimized side effects. However, IVIG therapy can be accompanied by adverse reactions ranging from mild symptoms like headaches and fatigue to more severe conditions such as allergic reactions, necessitating careful monitoring and preemptive measures by healthcare providers to mitigate these effects. Recent advancements have seen the development of subcutaneous alternatives and innovations like M254, a derivative with enhanced anti-inflammatory properties, showing promise in clinical trials for providing a more potent and better-tolerated treatment option than traditional IVIG, particularly for autoimmune conditions.

The demand for IVIG is driven by its diverse medical applications, effectiveness in treating rare diseases, and its increasing use in early intervention and maintenance therapy for chronic conditions. Technological advancements in IVIG production have enhanced its safety and scalability, reducing side effects and improving overall tolerability for patients. Additionally, global health initiatives and specialized immunology centers have integrated IVIG into national treatment guidelines, promoting its use. Patient advocacy and education have further increased demand, as more patients seek access to this essential treatment. Regulatory support, particularly for orphan drugs, has expedited the availability of IVIG, enhancing access to this crucial medication in both established and emerging markets. These factors collectively underscore the growing importance of IVIG in modern healthcare, pointing towards an expanded role and increased adoption in medical settings globally.

Select Competitors (Total 24 Featured) -

• Bharat Serums and Vaccines Limited
• Biotest AG
• China Biologic Products, Inc.
• CSL Limited
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Kedrion S.p.A.
• LFB Group
• Octapharma AG
• Shanghai RAAS Blood Products Co., Ltd.
• Shire plc
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.